BioStem Technologies Outlines $10M-$12M Annual OpEx Reduction Plan via In-House Manufacturing
BioStem Technologies (BSEM) has announced a strategic roadmap aimed at accelerating its path to breakeven. The company plans to implement annual cash operating expense cuts ranging from $10 million to $12 million by transitioning toward in-house manufacturing, which is targeted for implementation in the first half of 2027. The third quarter marks BioStem's second full period operating with a primary focus on hospital-based business models. Management is currently prioritizing execution of this cost-reduction strategy to stabilize the company's financial position and improve long-term profitability.
Tickers: $BSEM